hsa-mir-613: Hsa-mir-613 is a microRNA that has been studied in various contexts [PMC2703952]. In multiple sclerosis (MS), hsa-mir-613 was found to be upregulated in peripheral blood, along with hsa-miR-142-3p and hsa-miR-140-5p, while hsa-miR-107 was downregulated [PMC9191563]. In non-small cell lung cancer (NSCLC), hsa-mir-613 was identified as a potential biomarker for radiosensitivity, along with other microRNAs [PMC8433590]. Hsa-mir-613 is predicted to regulate a similar set of target genes as hsa-miR-1, according to the miRecords database [PMC2703952]. It is involved in a negative autoregulatory feedback loop with SREBP-1c and LXRE to regulate LXRα [PMC3192659]. However, the concentrations of hsa-mir-613 were too low to be analyzed in certain contexts [PMC3942699]. Hsa-mir-613 is negatively regulated by multiple mRNAs, including ARPC1A, C5orf51, CORO1C, ELMO1, KCNJ2, NANP, OSTF1, PGD, SH3BGRL3, SPRED1, TSPAN4, and UST [PMC9191563]. Overall, hsa-mir-613 has been found to be upregulated in MS peripheral blood and NSCLC radiosensitivity and plays a role in regulating LXRα [PMC9191563][PMC8433590][PMC3192659].